Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2019: 96.39
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39
For more details click here

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2021.10(5): 502-506
DOI: https://doi.org/10.20546/ijcmas.2021.1005.057


Vaccines and SARS-CoV-2 Variants-An Indian Perspective
Mohammad Arfat Ganiyani1,2, Manas Pustake1, 2*,Isha Tambolkar3, Zaid Memon4 and Sunita Bhandari5
1Department of Microbiology, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, 400008, India
2Dedicated Jumbo COVID Hospital, MMRDA Ground, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051, India
3Department of Microbiology, BJ Government Medical College and Sassoon Hospital,
Pune, 411001, India
4Department of Medical Virology, MGM Medical College, Navi Mumbai, 410 219, India
5Department of Microbiology, S.M.B.T Institute of Medical Sciences and Research Center, Dhamangaon, Nashik, India
*Corresponding author
Abstract:

SARS (Severe Acute Respiratory Syndrome) Coronavirus-2 (SARS-CoV-2) is a highly contagious virus that infects humans and several mammals, resulting in Coronavirus disease-19 (COVID-19). Every time the virus replicates, there is a chance that a mutation will occur, resulting in the development of a phylogenetically distinct strain. The emergence of several strains of this virus has resulted in a second wave of the epidemic and a tremendous amount of strain on the national surveillance and health systems. However, if we want to mount the most effective resistance against COVID-19, we must do so against variants as well, and for doing so, we must first consider the virus's evolutionary capacity. To foresee the variants that will emerge, it is important to understand how SARS-CoV-2 mutates and what limits its evolution. So far, the receptor-binding spike protein has been the focus, but the virus is a trailblazer, expressing 26 proteins that communicate with a broad variety of host factors, so the possibilities for evolution are numerous and uncertain. A triple mutant strain could be India's next challenge, and collecting as much information as possible about it is crucial to defeat it before it creates havoc. To bring an end to the COVID-19 pandemic, widespread immunity to SARS-CoV-2 will be needed.


Keywords: Virus, mutations, vaccinations, Coronavirus-2, surveillance system
Download this article as Download

How to cite this article:

Mohammad Arfat Ganiyani, Manas Pustake, Isha Tambolkar, Zaid Memon and Sunita Bhandari. 2021. Vaccines and SARS-CoV-2 Variants–An Indian Perspective.Int.J.Curr.Microbiol.App.Sci. 10(5): 502-506. doi: https://doi.org/10.20546/ijcmas.2021.1005.057